Research ArticleCancer

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells

See allHide authors and affiliations

Science Translational Medicine  18 Jul 2018:
Vol. 10, Issue 450, eaaq1093
DOI: 10.1126/scitranslmed.aaq1093
PDF Container

Navigate This Article